More Evidence for Impact of Lung Cancer Targeted Therapy from Practice-Changing Trial

Share this content:
More evidence for impact of lung cancer targeted therapy from practice-changing trial
More evidence for impact of lung cancer targeted therapy from practice-changing trial
An international study involving Manchester researchers has found that for previously untreated lung cancer patients with a particular genetic change, a new targeted therapy is better than standard chemotherapy. Some patients with non-small cell lung cancer (NSCLC) have changes in the anaplastic lymphoma kinase (ALK) gene, which can drive the development of their cancer.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »